Optimization of Darunavir Therapy and Dosage Recommendations

• Status: Completed
• Trial end date: 2019-06-12
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess and characterize the variability observed in the response to darunavir therapy, an antiretroviral medication used against the Human Immunodeficiency Virus (HIV). More specifically, it aims to quantify variations in the drug's blood concentrations and determine the sources of such variability, both genetic and non-genetic. In light of this information, current dosage guidelines will then be reviewed.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Université Catholique de Louvain
• Collaborator: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
• Treatments: Darunavir

Criteria

Inclusion Criteria:

• Capable of giving informed consent

• HIV-positive

• Routinely followed at the Cliniques universitaires Saint-Luc

• Treated with darunavir

Inclusion Criteria (intensive sampling):

• Perfect adherence to treatment (as assessed by anamnesis and based on available PK data for each patient)

Exclusion Criteria:

• N/A